The distal lung contributes to asthmatic airway remodeling which is observed from early onset
of the disease. Cysteinyl leukotrienes (CysLT) play important role in the pathogenesis of
airway remodeling and antileukotrienes work to exert a certain degree of anti-inflammatory
effect. The cysteinyl leukotriene antagonist Montelukast has been in vivo shown to
significantly inhibit ovalbumin induced airway smooth muscle hyperplasia and subepithelial
fibrosis in sensitized mice. This study aims to evaluate if Montelukast could reverse airway
remodeling in asthma patients by a non-invasive approach-HRCT.